PT-141 (Bremelanotide): The FDA-Approved Peptide That Targets Desire
Peptide Guides

PT-141 (Bremelanotide): The FDA-Approved Peptide That Targets Desire

Complete guide to PT-141 bremelanotide, the FDA-approved melanocortin receptor agonist for sexual dysfunction. Mechanism, clinical trials, dosing, side effects, and comparisons to Viagra and Cialis.

By PeptideRundown Team •
⚠️ Medical Disclaimer: This article is for educational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
Peptide Guide · FDA-Approved · Sexual Health

PT-141 (Bremelanotide): The FDA-Approved Peptide That Targets Desire

The only FDA-approved treatment that works through the brain's melanocortin system to increase sexual desire. How it works, what the clinical trials show, and how it compares to Viagra and Cialis.

MC4R Agonist FDA-Approved (Vyleesi) Central Nervous System
2019
FDA Approval
Year
MC4R
Primary
Receptor Target
1,025
Molecular Weight
(Daltons)
1.75 mg
Approved Dose
(Subcutaneous)

Viagra and Cialis work on blood flow. PT-141 works on your brain.

That distinction matters more than you might think. Most sexual dysfunction treatments target plumbing. PT-141 targets desire itself, activating melanocortin receptors in the central nervous system to increase arousal at its source. It's also one of the few peptides with actual FDA approval behind it.

What This Guide Covers

This is an educational breakdown of PT-141 (bremelanotide), covering its mechanism, clinical trial data, dosing, side effects, and comparisons. It is not a recommendation to use PT-141 outside of medical supervision. Always consult a qualified healthcare provider before considering any peptide protocol.


PT-141 at a Glance

Compound Profile

PT-141 / Bremelanotide (Vyleesi)

Generic Name: Bremelanotide  |  Brand Name: Vyleesi  |  Type: Synthetic cyclic heptapeptide  |  Molecular Formula: C50H68N14O10  |  Molecular Weight: 1,025.2 Da  |  Origin: Derived from alpha-MSH / Melanotan II  |  Route: Subcutaneous injection (autoinjector)  |  FDA Approval: June 2019 (HSDD in premenopausal women)

Unlike its parent compound Melanotan II, PT-141 was specifically engineered to isolate the pro-sexual effects while reducing melanogenic (skin-darkening) activity. It targets the brain's arousal circuitry rather than acting on peripheral blood vessels.

For a deeper compound profile, visit PeptideArc.


How PT-141 Works

Every other sexual dysfunction drug on the market works downstream, targeting blood vessels or hormones. PT-141 goes upstream. It activates melanocortin receptors in the hypothalamus and limbic system, the regions that govern desire itself.

PT-141: Melanocortin Receptor Pathway
Central mechanism of action · MC4R activation · Dopamine release · Sexual arousal
PT-141 ADMINISTRATION Subcutaneous injection (1.75 mg) ↓ Crosses into CNS within 45 min KEY STEP Reaches hypothalamus & limbic system MC4R Binding RECEPTOR ACTIVATION Binds MC4R & MC3R in hypothalamus ↓ Activates sexual arousal circuitry KEY STEP Central arousal pathway engaged Dopamine NEUROTRANSMITTER Increases dopamine in medial preoptic area ↓ Modulates oxytocin signaling KEY STEP Sexual motivation & desire increase Arousal PHYSIOLOGICAL Hypothalamic signal reaches genital tissue ↓ Physical arousal follows central signal KEY OUTCOME Both desire & physical readiness

Melanocortin Receptor Activation

PT-141 is a melanocortin receptor agonist. It binds primarily to MC4R and to a lesser degree MC3R in the hypothalamus and limbic system. These receptors sit at the center of the brain's sexual arousal circuitry.

When PT-141 activates MC4R, it increases dopamine release in the medial preoptic area (a region critical to sexual motivation), activates hypothalamic pathways governing arousal, and modulates oxytocin signaling (Pfaus et al., 2004). It bypasses the vascular system entirely.

Desire vs. Arousal: Why the Brain Matters

Sexual response has two distinct components: desire (wanting) and arousal (physical readiness). PDE5 inhibitors like Viagra address arousal by increasing blood flow to erectile tissue. But if the desire isn't there, blood flow alone won't fix the problem.

PT-141 targets desire. That's why it works in populations where Viagra fails, particularly women with HSDD and men whose erectile dysfunction has a psychological or motivational component.

Key Finding

In animal models, PT-141 induced erections in male rats and lordosis behavior in female rats through central nervous system pathways, independent of peripheral blood flow changes (Martin et al., 2002).

The Broader Melanocortin System

The melanocortin system regulates far more than skin pigmentation. MC4R specifically is involved in sexual function, energy homeostasis, cardiovascular regulation, and pain modulation.

This is why PT-141 can cause side effects like nausea and blood pressure changes. It's activating a system with broad physiological reach.


FDA Approval: Vyleesi

On June 21, 2019, the FDA approved bremelanotide (Vyleesi) for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It was only the second drug ever approved for this indication, following flibanserin (Addyi) in 2015.

Approval DetailInformation
DateJune 21, 2019
IndicationHSDD in premenopausal women
ManufacturerAMAG Pharmaceuticals (licensed from Palatin Technologies)
DeliverySingle-dose autoinjector (1.75 mg)
DosingAs needed, at least 45 min before activity
Max FrequencyOnce per 24 hours, max 8 doses per month
Onset45 minutes to 2 hours
DurationUp to 12 hours (varies by individual)

The approval was based on two pivotal Phase 3 trials: RECONNECT-1 and RECONNECT-2.

Important

Vyleesi is not approved for men, postmenopausal women, or erectile dysfunction. Off-label use exists, but clinical data in men is more limited.


Clinical Evidence

RECONNECT Trials (Women with HSDD)

The two Phase 3 RECONNECT trials enrolled over 1,200 premenopausal women diagnosed with HSDD. Both were randomized, double-blind, placebo-controlled studies lasting 24 weeks.

Phase 3 Trial Data

RECONNECT Results

Participants: 1,247 premenopausal women  |  Duration: 24 weeks  |  Dose: 1.75 mg subcutaneous, as needed  |  Primary Endpoints: Change in desire (FSFI-D) and distress (FSDS-DAO) scores

OutcomeBremelanotidePlacebo
Desire score (FSFI-D)+0.57+0.21
Distress score (FSDS-DAO)–0.72–0.41
Satisfying events (per month)+0.7+0.4
Responder rate (desire)~35%~22%

The effect sizes were modest but statistically significant (Kingsberg et al., 2019). Critics noted the clinical relevance is debatable. Supporters pointed out that HSDD is notoriously difficult to treat and any measurable improvement in desire is meaningful.

Male Erectile Dysfunction Studies

PT-141 has been studied in men with erectile dysfunction in earlier-phase trials with encouraging results. A Phase 2 trial in men with ED who had failed to respond to sildenafil showed that PT-141 produced erections sufficient for intercourse in a significant percentage of participants.

ParameterDetail
Participants342 men with ED
DesignRandomized, placebo-controlled, dose-ranging
Dose range0.3 mg to 10 mg (intranasal)
Key findingSignificant erectile response at doses of 4 mg and above

This was significant because these men had already failed on Viagra (Diamond et al., 2006). A separate study found dose-dependent increases in erectile function, including in men with diabetes-related ED (Rosen et al., 2004).

Psychogenic ED

PT-141 may be particularly useful for psychogenic ED, where the problem originates in the brain rather than the vasculature. Since it works centrally, it addresses the psychological and motivational components that PDE5 inhibitors cannot. No large-scale trials have been completed for this specific indication, but the mechanism strongly supports its potential.


Dosing Protocols

Important

These are based on FDA-approved labeling and clinical research protocols. Always work with a qualified provider.

FDA-Approved Dosing (Vyleesi)

ParameterRecommendation
Dose1.75 mg
RouteSubcutaneous injection (abdomen or thigh)
TimingAt least 45 minutes before anticipated activity
Max frequencyOnce per 24 hours
Monthly limit8 doses per month
Onset45 minutes to 2 hours
DurationUp to 12 hours (varies)

Research Dosing (Off-Label / Men)

Dosing in male studies has varied. The following reflects protocols from clinical trials.

ParameterDetail
Dose range studied0.5 mg to 2 mg (subcutaneous)
Common research dose1 mg to 2 mg
RouteSubcutaneous injection
Timing30 to 60 minutes before activity
Warning

Higher doses do not necessarily produce better results but do increase the likelihood of nausea and blood pressure elevation. More is not better with this peptide.

If using lyophilized powder (research setting), follow standard peptide reconstitution with bacteriostatic water. See our reconstitution guide for step-by-step instructions.


Side Effects and Safety

The side effect profile is well-characterized from the RECONNECT trials and other clinical studies. Nausea is by far the most common complaint.

Common Side Effects

Side EffectFrequencyNotes
Nausea~40%Most common; usually mild to moderate, resolves within hours
Flushing~20%Facial and upper body warmth and redness
Headache~11%Typically mild
Injection site reactions~5–6%Bruising, redness, itching at injection site
Blood pressure increaseCommonTypically 2–6 mmHg systolic; resolves within 12 hours

Less Common

Mild Concerns

Fatigue following use. Dizziness in a small percentage of users. Nasal congestion (reported in intranasal formulation studies).

Serious Concerns

Hyperpigmentation with repeated use (darkening of skin, gums, or breasts). Persistent blood pressure elevation in those with cardiovascular risk factors.

Contraindications

PT-141 is contraindicated in patients with uncontrolled hypertension or cardiovascular disease due to its transient blood pressure effects. It should not be used alongside flibanserin (Addyi). It should not be used in pregnancy.


PT-141 vs. Viagra vs. Cialis

This is the comparison most people want. The three drugs could not be more different in how they work.

FeaturePT-141Viagra (Sildenafil)Cialis (Tadalafil)
MechanismMC receptor agonist (brain)PDE5 inhibitor (blood vessels)PDE5 inhibitor (blood vessels)
Primary targetSexual desire + arousalErectile blood flowErectile blood flow
Works in womenYes (FDA-approved)Generally noGenerally no
Works in menYes (off-label)Yes (FDA-approved)Yes (FDA-approved)
RouteSC injectionOral tabletOral tablet
Onset45 min to 2 hours30–60 min30–60 min
DurationUp to 12 hours4–6 hoursUp to 36 hours
Addresses desireYesNoNo
Common side effectsNausea, flushingHeadache, flushing, visual changesHeadache, back pain, flushing
BP effectSlight increaseDecreaseDecrease

When PT-141 May Be Better

Low desire is the primary issue. PDE5 inhibitors haven't worked. Female sexual dysfunction. Psychological or motivational ED where the brain is the bottleneck.

When PDE5 Inhibitors Are Better

Vascular ED with clear blood flow limitation. Preference for oral dosing. Well-established safety profile with decades of data. Cost and accessibility (generics widely available).

Bottom Line

PT-141 and PDE5 inhibitors solve different problems. One addresses want. The other addresses can. Some people need both.


PT-141 vs. Flibanserin (Addyi)

Since both are FDA-approved for HSDD in premenopausal women, this comparison comes up frequently.

FeaturePT-141 (Vyleesi)Flibanserin (Addyi)
DosingAs needed (injection)Daily (oral pill, 100 mg at bedtime)
Onset45 min to 2 hours4–8 weeks of daily use
MechanismMC4R agonist5-HT1A agonist / 5-HT2A antagonist
Alcohol restrictionNoneSevere (risk of hypotension and syncope)
Common side effectsNausea, flushingDizziness, sleepiness, nausea
REMS programNoYes (due to alcohol interaction)
ConvenienceAs-needed, no daily commitmentMust take every night for weeks

PT-141 has a clear advantage for women who don't want a daily medication or who drink alcohol. Flibanserin's alcohol restriction and mandatory REMS certification for prescribers have significantly limited its adoption.


Who Might Benefit

Based on clinical data and the mechanism of action, PT-141 may be appropriate for several populations.

FDA-Approved

Premenopausal Women with HSDD

The only FDA-approved indication. Supported by two pivotal Phase 3 trials with over 1,200 participants.

Off-Label (Studied)

Men with ED Unresponsive to PDE5 Inhibitors

Phase 2 data supports efficacy in men who failed sildenafil. Many men's health clinics prescribe it off-label.

Off-Label (Mechanism-Based)

Men with Psychogenic ED

Where desire or arousal initiation is the core issue. The central mechanism directly addresses motivational components.

Combination Use

Desire Discrepancy Cases

Couples where desire discrepancy is the problem rather than physical function. Can be combined with PDE5 inhibitors under medical supervision.


Legal Status and Availability

United States

FDA-approved as Vyleesi (prescription only). Also available as research peptide. Autoinjector costs approximately $800–$1,000 for a pack of four.

European Union

Not approved. Available through research chemical suppliers.

Australia

Not TGA-approved. Available through compounding pharmacies in some cases.

Canada

Not approved by Health Canada.

Research-grade PT-141 is available from peptide suppliers at significantly lower cost, though without the quality assurance of pharmaceutical manufacturing. Check our peptide legality guide for full details.


Frequently Asked Questions

What does PT-141 actually feel like?
Most users describe a gradual increase in sexual desire and arousal starting about 45 minutes to 2 hours after injection. It's not an immediate or overwhelming effect. Some describe a "warmth" or heightened sensitivity to physical contact. Nausea is common in the first hour or two, particularly with the first few uses.
How long does PT-141 last?
Effects typically persist for 6 to 12 hours, though this varies. The peak effect is usually 2 to 4 hours after injection. Some users report residual effects into the following day.
Can men use PT-141?
Yes, though it's not FDA-approved for men. Clinical trials have shown it produces measurable improvements in erectile function, particularly in men who didn't respond to Viagra. Many men's health clinics prescribe it off-label.
Is PT-141 the same as Melanotan II?
No. PT-141 is a metabolite derivative of Melanotan II, but with key differences. PT-141 is a cyclic heptapeptide (7 amino acids) that primarily targets MC4R. Melanotan II is a larger peptide that activates multiple melanocortin receptors, causing significant skin tanning, appetite suppression, and sexual arousal. PT-141 causes less skin darkening than Melanotan II, though some hyperpigmentation can still occur with repeated use.
Can you combine PT-141 with Viagra or Cialis?
Some providers do prescribe this combination. PT-141 addresses desire (brain) while PDE5 inhibitors address blood flow (peripheral). The combination can be effective for men with both motivational and vascular components. However, monitor blood pressure carefully. PT-141 slightly raises blood pressure while PDE5 inhibitors lower it. The effects may partially offset, but individual responses vary.
Does PT-141 work for everyone?
No. In the RECONNECT trials, about 35% of women were classified as responders based on desire improvement. That means a majority did not see clinically meaningful benefit. Response rates in men appear higher in the available data, but larger trials are needed.
Are there long-term risks?
Long-term safety data is limited. The main concerns are hyperpigmentation with chronic use (which may or may not be reversible), blood pressure effects in people with cardiovascular risk factors, and unknown effects of chronic MC4R activation on appetite, weight, and metabolism. The FDA label recommends limiting use to 8 doses per month partly due to these unknowns.
Why is PT-141 an injection and not a pill?
PT-141 is a peptide, and peptides are generally broken down by digestive enzymes before they can be absorbed. Subcutaneous injection bypasses the GI tract and delivers the drug directly into the bloodstream. An intranasal formulation was studied earlier but was abandoned due to blood pressure concerns at the nasal doses required.

The Bottom Line

Summary

PT-141 is the only approved treatment that works through the brain's melanocortin system to increase desire rather than simply improving blood flow. For the right patient, it fills a gap that no other drug currently addresses.

For women with HSDD, it offers an as-needed alternative to daily flibanserin without alcohol restrictions. For men, the off-label evidence suggests real utility, especially in cases where PDE5 inhibitors have failed or where the problem is motivational rather than vascular.

The trade-offs are real. Nausea affects a large percentage of users. It requires injection rather than a pill. And the effect sizes in clinical trials, while statistically significant, were modest. Not everyone responds.

But for the right patient, PT-141 fills a gap that no other drug currently addresses. It treats the wanting, not just the doing.

Medical Disclaimer
This article is for educational and informational purposes only and does not constitute medical advice. PT-141 (bremelanotide) is an FDA-approved prescription medication (Vyleesi) that should only be used under the guidance of a qualified healthcare provider. Do not self-treat. Always discuss potential risks, side effects, and drug interactions with your doctor before starting any peptide protocol.

References

Pfaus JG et al. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci USA. 2004;101(27):10201-4. PubMed
Martin WJ et al. Pharmacological profile of a melanocortin receptor agonist on penile erection. Eur J Pharmacol. 2002;454(1):71-9. PubMed
Kingsberg SA et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. PubMed
Diamond LE et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628-38. PubMed
Rosen RC et al. Bremelanotide (PT-141): a melanocortin receptor agonist for the treatment of erectile dysfunction. Int J Impot Res. 2004;16(Suppl 1):S8-S13. PubMed

Related reading:

What Are Peptides? Beginner's Guide  ·  Melanotan II Complete Guide  ·  Peptide Side Effects: What to Know  ·  Are Peptides Legal? FDA Regulations 2026

For compound profiles and sourcing info, visit PeptideArc.